Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
Chun-Ju Lin,1,2 Yi-Yu Tsai1,2 1School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; 2Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan Purpose: The purpose of this study was to report on the axial length, refrac...
Saved in:
Main Authors: | Lin CJ, Tsai YY |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2016
|
Subjects: | |
Online Access: | https://doaj.org/article/ce50a7fda98f4a9faa716882e547e831 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
by: Obata S, et al.
Published: (2019) -
Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
by: Majid Abrishami, et al.
Published: (2021) -
Metabolism in Retinopathy of Prematurity
by: Yohei Tomita, et al.
Published: (2021) -
Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
by: Narayanan R, et al.
Published: (2016) -
Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
by: Alsaedi NG, et al.
Published: (2021)